Semaglutide, Tirzepatide and Clinically Recorded Alcohol‐Related Outcomes in Type 2 Diabetes: A Target Trial Emulation
Semaglutid, Tirzepatid und klinisch erfasste alkoholbezogene Outcomes bei Typ-2-Diabetes: Target-Trial-Emulation
Diabetes, Obesity and Metabolism · 2026-11-03
DOI: 10.1111/dom.71470 ↗Auf einen Blick
Bei Erwachsenen mit Typ-2-Diabetes waren Semaglutid und Tirzepatid mit niedrigeren Raten klinisch erfasster AUD-assoziierter Hospitalisationen oder Notaufnahmen verbunden als SGLT2i. Zwischen Semaglutid und Tirzepatid zeigte sich kein Unterschied.
Fragestellung
Vergleicht das Risiko eines erstmals klinisch erfassten Alkoholgebrauchsstörungs-(AUD-)Outcomes unter Semaglutid, Tirzepatid oder SGLT2i bei Erwachsenen mit Typ-2-Diabetes?
Methode
Target-Trial-Emulation mit de-identifizierten EHR-Daten aus dem TriNetX-Netzwerk (Juni 2022 bis Januar 2025); 1:1 Propensity-Score-Matching; Cox-Modelle; Sensitivitäts- und Subgruppenanalysen.
Ergebnisse
Semaglutid vs. SGLT2i: 2,42 vs. 4,53 pro 1000 Personenjahre; HR 0,54 (95 %-KI 0,45–0,64). Tirzepatid vs. SGLT2i: 2,34 vs. 3,98; HR 0,61 (95 %-KI 0,46–0,83). Semaglutid vs. Tirzepatid: HR 0,98 (95 %-KI 0,73–1,31).
Schlussfolgerung der Autor:innen
Bei Erwachsenen mit Typ-2-Diabetes waren Semaglutid und Tirzepatid mit niedrigeren Raten klinisch erfasster AUD-assoziierter Outcomes verbunden als SGLT2i; zwischen beiden GLP-1RA bestand kein Unterschied.
Kernaussagen
- Semaglutid vs. SGLT2i: HR 0,54 (95 %-KI 0,45–0,64)
- Tirzepatid vs. SGLT2i: HR 0,61 (95 %-KI 0,46–0,83)
- Semaglutid vs. Tirzepatid: kein Unterschied im Risiko
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
At a glance
Journal article in Diabetes, Obesity and Metabolism, published online on 2026-11-03. Written by Huilin Tang and 7 co-authors. Institution: Center for Preventative Ophthalmology and Biostatistics, Department of Ophthalmology, University of Pennsylvania Perelman School of Medicine, Philade…. 46 references. The full text is freely available (open access, CC BY 4.0). Funded by: American Heart Association, NIH HHS, National Institutes of Health.
Topics: Diabetes mellitus
Abstract (original language)
Aims
To compare the risk of incident alcohol use disorder (AUD) among adults with Type 2 diabetes (T2D) initiating semaglutide, tirzepatide or sodium‐glucose cotransporter‐2 inhibitors (SGLT2i). Materials and Methods We conducted a target trial emulation using de‐identified electronic health record data from the TriNetX research network (June 2022–January 2025). Adults with T2D newly initiating semaglutide, tirzepatide or an SGLT2i were included. The primary outcome was clinically recorded hospitalization or emergency department (ED) visits for AUD. Cox proportional hazards models with 1:1 propensity score matching (PSM) estimated hazard ratios (HRs) and 95% CIs. Sensitivity and subgroup analyses as well as secondary outcomes assessed the robustness of the findings.
Results
During a mean follow‐up of 0.81–1.02 years, the incidence rates (IRs) of clinically recorded hospitalization or ED visits for AUD were 2.42 versus 4.53 per 1000 person‐years for semaglutide versus SGLT2i, with an HR of 0.54 (95% CI, 0.45–0.64). Similarly, the IRs were 2.34 versus 3.98 per 1000 person‐years for tirzepatide versus SGLT2i, with an HR of 0.61 (95% CI, 0.46–0.83). In the direct comparison of semaglutide versus tirzepatide, IRs were 2.43 and 2.36 per 1000 person‐years, respectively, with no difference in risk (HR, 0.98; 95% CI, 0.73–1.31). Results were consistent across sensitivity and subgroup analyses and secondary outcomes.
Conclusions
In adults with T2D, semaglutide and tirzepatide were associated with lower rates of clinically recorded AUD‐related outcomes than SGLT2i, with no difference between the two GLP‐1RA medications.
Subjects
Author keywords
Authors and institutions
- Center for Preventative Ophthalmology and Biostatistics, Department of Ophthalmology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
- The Center for Health AI and Synthesis of Evidence (CHASE), University of Pennsylvania, Philadelphia, Pennsylvania, USA.
- Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
- The Graduate Group in Applied Mathematics and Computational Science, School of Arts and Sciences, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
- Mental Illness Research, Education and Clinical Center, Crescenz Veterans Affairs Medical Center and Department of Psychiatry, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
- Penn Medicine Center for Evidence-Based Practice (CEP), University of Pennsylvania, Philadelphia, Pennsylvania, USA.
ORCID profiles: Huilin Tang, Bingyu Zhang, Yong Chen
Funding
- American Heart Association
- NIH HHS
- National Institutes of Health
Cite
APA
Tang, H., Zhang, B., Lu, Y., Lu, Y., Wang, H., Davis, C. N., Kranzler, H. R., & Chen, Y. (2026). Semaglutide, Tirzepatide and Clinically Recorded Alcohol‐Related Outcomes in Type 2 Diabetes: A Target Trial Emulation. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.71470
Vancouver
Tang H, Zhang B, Lu Y, Lu Y, Wang H, Davis CN, et al. Semaglutide, Tirzepatide and Clinically Recorded Alcohol‐Related Outcomes in Type 2 Diabetes: A Target Trial Emulation. Diabetes, Obesity and Metabolism. 2026. doi:10.1111/dom.71470
BibTeX
@article{Tang2026,
author = {Tang, Huilin and Zhang, Bingyu and Lu, Ying and Lu, Yiwen and Wang, Haoyuan and Davis, Christal N and Kranzler, Henry R and Chen, Yong},
title = {Semaglutide, Tirzepatide and Clinically Recorded Alcohol‐Related Outcomes in Type 2 Diabetes: A Target Trial Emulation},
journal = {Diabetes, Obesity and Metabolism},
year = {2026},
doi = {10.1111/dom.71470}
}
EUVIMED